Work

Abstract 2174: Sirpiglenastat (DRP-104), a novel broad acting glutamine antagonist, has therapeutic potential in targeting KEAP1-mutant lung cancer

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-2174

Authors: Sarah LeBoeuf, Ray Pillai, Shih Ming Huang, Triantafyllia Karakousi, Warren Wu, Volkan Sayin, Robert Wild, Thales Papagiannakopoulos

Institutions: New York University, University of Gothenburg

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282980921

Cites:

Cited by:

Related to: 10